Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes
Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on LinkedIn:
“Insights into the management of Leptomeningeal disease (LMD) and clinical outcomes:
I would like to add the following comments:
In ER-positive breast cancer, Abemaciclib should be considered the CDK4/6 inhibitor of choice due to its superior penetration through the blood-brain barrier (BBB).
Intrathecal therapy remains underutilized in both research and clinical management settings.
Lumbar puncture for direct genomics analysis is also underutilized and warrants further exploration.
The role of PD-1 and PD-L1 inhibitors in patients with PD-L1 positive disease deserves further discussion (response rates exceeds 30%).”
Proceed to the article.
Source: Kefah Mokbel/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023